Save the date next month and RP

Posted:
26
August 2010

Save the date next month and RPL will see you for the American College of Clinical Pharmacologys (ACCP) 39th Annual Meeting taking place 12th to 14th September 2010 in Baltimore, Maryland.

The Annual Meeting will cover a wide array of topics such as international drug development and collaboration, pharmacometrics, pharmacogenomics, and specific sessions relating to biologics, nutraceuticals, and drug therapy in special populations, providing an ideal platform for scientists of various disciplines to meet and discuss areas of common interest.

We invite you to come down and see us at our booth that will be located in Harborside DE zone at the Baltimore Marriott Waterfront Hotel. In addition we are pleased to announce that Dr Jorg Taubel, MD., FFPM., Clinical Pharmacologist and Principal Investigator at Richmond Pharmacology, is due to present at the Annual Meeting where he will address two core topics of discussion, namely:

  • 132 - Repeated Dosing of Strontium Ranelate 4G Over 15 days Does Not Prolong QTC Interval in Healthy Volunteers
  • 133 - PET500 A Newly Formulated Tetracaine Product is Effective in Reducing Penile Sensitivity  

Dr Taubel�s presentation has been scheduled for Poster Session 2 on Monday, 13th September, 2010 from 6 PM � 7:30 PM and there are also a number of other learning activities in store, so be sure not to miss out on what is expected to be both an educational and rewarding conference.

For more information on the Annual Meeting click here for further details or click here to view the preliminary meeting program.

We look forward to seeing you next month in Baltimore!

Latest news

Upcoming Event

ACCP 2020, Translating Clinical Pharmacology Research into Patient-centered Care

21 - 23 September 2020
Dr. Jorg Taubel will be presenting posters that explore the subjects of cardiac health and diabetes.
View event

Richmond Pharmacology is delighted to confirm partnership with Intellia Therapeutics

October 20, 2020
Phase I study of Intellia Therapeutic’s NTLA-2001 for the treatment of hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN)
Read more

Richmond Pharmacology supports ReViral with the development of Sisunatovir

September 9, 2020
ReViral has confirmed the FDA has granted Fast Track designation to Sisunatovir.
Read more

Richmond Pharmacology helps UK patients gain early access to ultra-rare disease drug Lumasiran

August 17, 2020
Richmond Pharmacology early phase drug development update.
Read more